Omega-3 (EPA + DHA)

Membrane Incorporation: The Foundation Everything Else Sits On#

EPA and DHA don't work through a receptor — they work by becoming part of you. Once absorbed (via chylomicrons, with a fat-containing meal), they're progressively swapped into the phospholipid bilayer of every cell membrane in the body, partially displacing arachidonic acid (AA), the omega-6 precursor that dominates a Western diet. This is why the effect is slow and structural: RBC membrane incorporation ("Omega-3 Index") takes 3–4 months to plateau on a stable dose, and washout is equally slow. Missing a day or two is irrelevant; dosing once daily is fine.

The practical consequence: most of what omega-3 does downstream — anti-inflammatory tone, mTOR sensitivity, triglyceride handling, membrane fluidity — is a function of how much EPA/DHA is sitting in your membranes, not how much is in your blood this afternoon.

Eicosanoid Rebalancing and Pro-Resolving Mediators#

The headline anti-inflammatory mechanism is a substrate swap. AA-derived 2-series prostaglandins and 4-series leukotrienes (potently pro-inflammatory) are partially replaced by EPA-derived 3-series PGs and 5-series LTs, which are markedly weaker. On top of that, EPA and DHA are the precursor pool for resolvins, protectins, and maresins — specialized pro-resolving mediators (SPMs) that actively shut down inflammation rather than just blunt it.

"EPA and DHA give rise to mediators that have a lower inflammatory potency than those formed from AA, thereby shifting the balance towards resolution of inflammation." — Calder PC, Biochemical Society Transactions, 2017

For lifters running harsh orals or training through tendinopathy, this is the mechanism behind the "joints feel less glassy" effect — you're dampening the inflammatory signal at its lipid substrate, not masking it with an NSAID.

Anabolic Sensitization (mTOR / p70S6K)#

EPA/DHA enrichment of sarcolemmal phospholipids increases muscle's anabolic sensitivity to amino acids and insulin. Membranes with more long-chain n-3 PUFA show amplified mTOR/p70S6K signaling in response to a leucine-rich feed, and human studies confirm the translational output: higher MPS rates under hyperaminoacidemia-hyperinsulinemia after 8 weeks of supplementation.

"Omega-3 FA supplementation significantly increased the rate of muscle protein synthesis in response to hyperaminoacidemia-hyperinsulinemia in older adults." — Smith GI, Atherton P, Reeds DN, et al., Clinical Science, 2011

"Omega-3 fatty acids can amplify anabolic signaling and MPS responses to feeding and interventions such as resistance exercise." — McGlory C, Calder PC, Nunes EA, Frontiers in Nutrition, 2019

There's also a catabolism side: omega-3 downregulates atrogenes like MuRF1 and MAFbx, which is the mechanism most relevant to lean-mass retention in a cut or during forced disuse. This is not a dramatic, standalone anabolic — it's a sensitization effect that pays off when protein intake and training stimulus are already in place.

Hepatic Lipid Handling (SREBP-1c ↓ / PPAR-α ↑)#

In the liver, EPA/DHA suppress SREBP-1c (the master transcription factor for de novo lipogenesis) and activate PPAR-α, upregulating fatty acid β-oxidation. Net effect: less VLDL-TG exported, more fatty acid burned. At pharmacological doses this produces a clinically meaningful triglyceride drop.

"Pharmacological doses (2–4 g/day) of EPA+DHA reduce triglyceride levels by 20%–30% in patients with elevated TG." — Skulas-Ray AC, Wilson PWF, Harris WS, et al., Circulation, 2019

This is the mechanism that makes omega-3 a core piece of the on-cycle lipid kit. It won't rescue harsh-oral dyslipidemia alone — that's what a statin is for — but it meaningfully blunts the TG excursion and contributes to CV event reduction in the statin-treated, elevated-TG population (the REDUCE-IT finding with 4 g/day pure EPA).

Membrane Fluidity, Mitochondria, and Endothelial Function#

DHA in particular increases membrane fluidity due to its six double bonds and its preferential incorporation into neural and mitochondrial membranes. Downstream consequences relevant to physique-focused users:

• Mitochondrial respiration kinetics improve — part of why the effect on muscle quality and endurance is structural rather than acute
• Endothelial NO signaling is modestly enhanced, with a small but real reduction in platelet aggregation — useful alongside the BP/hematocrit load of AAS
• Neural membranes (brain, retina) depend heavily on DHA; this is where the cognition and mood signal comes from

The through-line: omega-3 is a membrane drug. You're not taking a supplement that does something today — you're rebuilding the lipid environment that every other signaling pathway operates inside. That's why dose response plateaus, why timing doesn't matter, and why the payoff shows up over months rather than weeks.

Common (most users)#

• Fishy burps / reflux — the classic complaint. Freeze the softgels (slows gastric dissolution past the lower esophageal sphincter), dose with a fat-containing meal, and switch to an rTG or enteric-coated product. Cheap ethyl ester capsules are the worst offenders.
• Loose stool or mild GI upset — split the dose AM/PM with food, or drop back 1 g and titrate up over a week.
• Rancid aftertaste — not a "side effect," it's a spoiled product. Oxidized fish oil is mildly *pro-*inflammatory. Toss the bottle and buy IFOS-certified or third-party-tested (Carlson, Nordic Naturals, Kirkland Signature TG, Sports Research).
• Slight increase in bruising — cosmetic, dose-dependent, not clinically significant at 2–4 g/day in otherwise healthy users.

Uncommon (dose-dependent or individual)#

• LDL-C creep on DHA-heavy products — DHA can push LDL-C up 3–10% in some users. If your LDL/ApoB is already borderline on cycle, switch to an EPA-dominant product (≥2:1 EPA:DHA) or pharma-grade icosapent ethyl.
• Prolonged bleeding time / easier bruising at ≥4 g/day — back off to 2–3 g in the week before any elective procedure, dental work, or heavy BJJ/contact sport block.
• Palpitations / ectopy — if you notice new-onset palpitations after starting 4–5 g/day, drop the dose and get a rhythm check (see AFib signal below).
• Elevated fasting glucose (transient, minor) — reported inconsistently in older DHA literature; not meaningful at community doses but worth noting if you're already tracking glucose on GH/slin.

"Pharmacological doses (2–4 g/day) of EPA+DHA reduce triglyceride levels by 20%–30% in patients with elevated TG." — Skulas-Ray et al., Circulation 2019

Bloodwork to check at 8 weeks on cycle: full lipid panel + ApoB, hsCRP, and — if you want an objective intake measure — an Omega-3 Index (RBC EPA+DHA %). Target ≥8%.

Rare but serious#

• Incident atrial fibrillation. This is the real caveat and the one the community under-discusses. Pooled analyses of the pharma-dose trials (REDUCE-IT, STRENGTH, OMEMI, VITAL-Rhythm) show a dose-dependent ~25% relative-risk increase in new-onset AFib at ≥1 g/day of prescription omega-3.

"Marine n-3 FA supplementation was associated with an increased risk of incident AF (RR, 1.25 [95% CI, 1.07–1.46])." — Gencer et al., Circulation 2021

Absolute risk in a young, healthy lifter is small, but the risk rises with dose. If you have a family history of AFib, a personal history of palpitations, or you're stacking stimulants + T3 + high-dose AAS (all pro-arrhythmic), keep total EPA+DHA ≤3 g/day and investigate any new palpitations, lightheadedness, or exercise-induced irregular pulse promptly.

• Clinically significant bleeding — essentially only seen in users on anticoagulants/antiplatelets, or at very high doses around surgery or major trauma. Pause fish oil 7 days before elective surgery as standard practice.
• Allergic reaction — fish or shellfish allergy is a contraindication (see below). Algal EPA/DHA is the workaround.

Hard contraindications#

• Active anticoagulant therapy (warfarin, DOACs, dual antiplatelet therapy) — do not add 3–4 g/day fish oil without coordinating with the prescribing physician. Additive bleeding risk is real.
• Imminent elective surgery — stop 7 days prior.
• Personal history of atrial fibrillation or active arrhythmia workup — stay at population-dose levels (≤1 g/day) or off entirely until cleared; the AFib signal at pharma doses is not worth the lipid benefit when you have other tools.
• Fish or shellfish allergy — use algal-derived EPA/DHA instead.

Gender, pregnancy, and PCT notes#

Omega-3 has no hormonal activity, does not affect the HPTA, and requires no PCT. Dosing is identical for men and women. DHA is actively recommended during pregnancy for fetal neurodevelopment — standard 2 g/day EPA+DHA is considered safe in pregnancy provided the product is mercury-tested (IFOS or equivalent); avoid cod liver oil in pregnancy because of the preformed vitamin A load. Not a controlled substance, legal OTC everywhere, no cycle structure required — this is a year-round base-layer supplement.